RN7SL453P

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, RN7SL453P Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RN7SL453P data layer compared with 5 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher RN7SL453P Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RN7SL453P expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, UCEC, and LUAD are the cancer types where RN7SL453P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
ACCDFSMedianAll0.0460.753<.00136view →
UCECDFSMedianAll0.9550.611.0168view →
LUADOSMedianAll0.2760.697.0403view →
Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RN7SL453P–ACC (DFS)

Kaplan–Meier survival curve for RN7SL453P mutant vs wild-type samples in ACC.

Open the ACC breakdown →

Exploration